The shares of Strides Arcolab (Strides) surged by 17 per cent to Rs 172.05 after Onco Therapies (OTL), the joint venture between Strides and Aspen Pharmacare Holdings, concluded a licensing and supply agreement with GlaxoSmithKline (GSK).

<tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>Under the agreement, OTL will license intellectual property and supply finished dosage form pharmaceuticals to GSK. OTL will recover the intellectual property development costs from and share the profits with GSK. The stock hit a high of Rs 179.80 and a low of Rs 144. </P></p><p class='TableClas'></p></table>


Strides Arcolab soars on striking in-licensing deal

DALAL STREET SPIKES

More From This Section

Idea shares fall after Q3 earnings disappoint

BofA-Merrill raises Indiabulls to 'buy', stock gains

Suzlon stocks jump 17% on CDR approval

Maruti Suzuki rallies as Q3 profit beats analyst's estimates

Explore News